

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets

(11) Publication number:

**0 091 026**  
**A2**

(12)

# EUROPEAN PATENT APPLICATION

(21) Application number: 83102958.2

(51) Int. Cl.<sup>3</sup>: C 12 Q 1/46

(22) Date of filing: 24.03.83

(30) Priority: 02.04.82 US 364899

(43) Date of publication of application:  
12.10.83 Bulletin 83/41(84) Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE(71) Applicant: Modrovich, Ivan Endre  
829 Via Alondra  
Camarillo California 93010(US)(72) Inventor: Modrovich, Ivan Endre  
829 Via Alondra  
Camarillo California 93010(US)(72) Inventor: Caris, Karen Rae  
1399 North Lucero Street  
Camarillo California 93010(US)(74) Representative: Patentanwälte Grünecker, Dr.  
Kinkeldey, Dr. Stockmair, Dr. Schumann, Jakob, Dr.  
Bezold, Meister, Hilgers, Dr. Meyer-Plath  
Maximilianstrasse 58  
D-8000 München 22(DE)

(54) Improved time-stable liquid cholesterol assay compositions.

(57) There is provided a stable cholesterol assay composition which comprises an aqueous solution of at least one bile acid or salt thereof being present in an amount of up to about 5mM; a nonionic surfactant present in an amount of from about 0.15 to about 1.5 percent volume by volume; a buffer in a concentration of from 0 to about 65 mM; and cholesterol oxidase in a concentration of at least about 0.2 KIU/l. Solution pH is from about 5.5 to about 8.5. Addition of cholesterol esterase, phenol, peroxidase and 4-amino-antipyrine provides a total cholesterol chromogen system.

EP 0 091 026 A2


14511:JPG

-1-


IMPROVED TIME-STABLE LIQUID  
CHOLESTEROL ASSAY COMPOSITIONS

Background of the Invention

It has been known to determine cholesterol in sera by the use of assay compositions based on cholesterol oxidase, presently from a microbial source. The reaction involved is:




For total cholesterol determination, bound cholesterol may be released by the inclusion of cholesterol esterase which yields cholesterol by the reaction:



The amount of cholesterol can be assayed by measuring the amount of oxygen consumed, the amount of cholest-4-en-3-one formed, or the amount of hydrogen peroxide formed.

A preferred way is to determine the amount of hydrogen peroxide formed by use of a chromogen system. A preferred chromogen system is one based on the presence of peroxidase from a horseradish source, phenol and antipyrine involving the reaction:



1           While most assay systems based on cholesterol oxidase  
can be made functional as prepared, they are prone to  
rapid degradation. As a consequence, the art early on  
liapholized (freeze-dried) the composition for reconsti-  
5           tution at the time of use. Liapholization is expensive  
and suffers from inaccuracy.

-           A need was recognized to provide a liquid assay  
system of controlled composition which would have an  
adequate shelf life for marketing purposes. As invented  
10           and described by one of us, and disclosed in EPC Applica-  
tion 80.104.568.3, filed 1 August, 1980, incorporated  
herein by reference, it was found that the presence of a  
material quantity, e.g., up to 50 percent by volume, of a  
polyhydroxy compound such as glycerol would induce long  
15           shelf life to a liquid assay composition. The invention  
enabled precise quality control to be exercised over the  
composition of the system, and enabled total reliability of  
the assay system as a tool. The system was formulated as a  
concentrate. Shelf life of the concentrate was more than  
20           adequate for industrial use and provided levels of stability  
theretofore unknown in the art.

          The polyhydroxy compound, while functional to stabilize  
the system against degradation, increases costs and, unless  
proper housekeeping procedures are followed, contaminates  
25           apparatus, affecting other tests, particularly triglyceride  
analysis.

          A desire has existed, therefore, for a liquid assay  
system which did not yield in performance, which could be  
sold as a single formulation for use as is without dilution  
30           and yet have an adequate shelf life to satisfy marketing  
requirements.

Summary of the Invention

It has now been found that utilizing basic constituents normally present in a cholesterol assay system, but exercising exacting control over concentration of bile acid or salts thereof, nonionic surfactant and buffer, as well as pH, one can formulate a stable cholesterol assay composition which does not require a polyhydroxy compound and yet exhibits projected shelf lives of 18 months or more at 4°C, and when used with a chromogen system, rapid completion times.

The base solution employed is an aqueous solution of at least one acidic compound which is a bile acid or salt thereof, present in a concentration of up to about 5 mM, preferably from about 0.2 to about 5 mM; a nonionic surfactant, preferably propylene glycol p-isooctylphenyl ether, present in a concentration of from about 0.15 to about 1.5 percent volume by volume, preferably from about 0.2 to about 0.6 percent volume by volume; from 0 to 65 mM of a buffer, preferably from 0.5 to 50 mM, and more preferably from 0.5 to 30 mM, the preferred buffer being potassium dihydrogen phosphate ( $\text{KH}_2\text{PO}_4$ ); and cholesterol oxidase in a concentration of at least 0.02 KIU/l, preferably at least 0.05 KIU/l, the solution having a pH of from about 5.5 to about 8.5, preferably from 6 to about 7.5.

Where it is desired to assay for total cholesterol, there is included in the composition a microbial cholesterol esterase present in a concentration of at least 0.07 KIU/l, preferably at least about 0.1 KIU/l.

The preferred composition is one containing a chromogen system for determination of hydrogen peroxide. The chromogen system preferably comprises phenol in a concentration of from 8 to about 35 mM; 4-aminoantipyrine in a

1 and peroxidase in a concentration sufficient to enable  
completion of a chromogen reaction, i.e., development of  
the pink quinoneimine dye to an intensity quantitative to  
hydrogen peroxide formed. For commercial practicality,  
5 they are provided in quantities sufficient to enable com-  
pletion of the reaction within 10 minutes at 37°C.  
- Preferably, the peroxidase is provided in a concentration  
of at least 30 KIU/l, and 4-aminoantipyrine to a concentra-  
tion of about 0.3 mM

10 There is preferably included in the composition a  
bacteriocide, with the preferred bacteriocide being  
2,4 dichlorophenol, present in a concentration of up to  
about 1 mM, preferably from about 0.4 to about 0.6 mM.

The compositions prepared in accordance with the  
15 instant invention are stable for at least 3 days at 41°C,  
which is equivalent to a projected shelf life of 18 months  
at 4°C or about 6 months at ambient temperature (25°C).

When a chromogen system is employed, completion of  
reaction preferably occurs within 10 minutes or less at  
20 37°C, with a color stability of at least an additional 30  
minutes.

The products are prepared by first forming an aqueous  
solution to which there is provided buffer, bile acid or  
salts thereof, and surfactant. Phenol, dichlorophenol and  
25 4-aminoantipyrine are added as required. This base com-  
position is adjusted, if required, to an acceptable pH  
range by addition of a suitable acid or base.

There is separately formed an aqueous solution con-  
taining the nonionic surfactant and the enzymes which are  
30 added. The base solution and the solution of the enzymes  
are then combined to form a net solution.

1  
Detailed Description

According to the present invention there is provided  
5 an assay solution for the determination of cholesterol in  
the liquids, including sera, and which display a protracted  
shelf life life, i.e., a shelf life of about 18 months or  
more at 4°C (refrigeration conditions). Long shelf life  
is primarily the result of control over concentration of  
10 buffer employed.

A stable cholesterol assay composition of the instant  
invention comprises an aqueous solution of at least one  
acidic compound which is a bile acid and/or a salt of a bile  
acid, the total of said acidic compound being present in an  
15 amount of up to about 5mM, preferably from about 0.2 to  
about 5 mM; a nonionic surfactant present in a concentration  
of from about 0.15 to about 1.5 percent volume by volume,  
preferably from about 0.2 to about 0.6 percent volume by  
volume; a buffer in a concentration of from 0 to about  
20 65 mM, preferably from about 0.5 to about 50 mM; cholesterol  
oxidase in a concentration of at least about 0.02 KIU/l,  
preferably at least 0.05 KIU/l, the solution having a pH of  
from about 5.5 to about 8.5.

For total cholesterol assay there is included micro-  
25 bial cholesterol esterase present in a concentration of at  
least about 0.07 KIU/l, preferably at least about 0.1  
KIU/l.

The preferred cholesterol assay composition includes  
a chromogen system for determination of hydrogen peroxide.

30 More particularly, the preferred chromogen cholesterol  
assay solutions of the instant invention provide, on a per-  
liter basis, phenol in a concentration of from about 8 to  
about 35 mM, preferably from about 15 to about 20 mM; bile  
acid and/or a salt of bile in a total amount up to about  
35 5.0 mM, preferably from about 0.2 to about 5 mM; a nonionic

14511

-6-

1 surfactant, preferably polyethylene glycol p-isooctylphenyl  
ether (TRITON X-100), in a concentration of from about 0.15  
to about 1.5 percent by volume, preferably from 0.2 to about  
0.6 percent volume by volume; a buffer in a concentration of  
5 from 0 to 65 mM, preferably from about 0.5 to about 50 mM;  
cholesterol oxidase in a concentration of at least ~~0.02~~ 0.02  
KIU/l; peroxidase, preferably in a concentration of at least  
about 30 KIU/l; and, if present, cholesterol esterase in a  
concentration of at least 0.07 KIU/l, preferably at least  
10 about ~~0.07~~ <sup>0.1</sup> KIU/l. Peroxidase and 4-aminoantipyrine are pro-  
vided in an amount sufficient to enable quantitative color-  
metric determination of the amount of hydrogen peroxide  
formed from oxidation of cholesterol. It is preferred that  
this occur within a 10-minute completion time at 37°C. To  
15 this end, it is preferred that 4-aminoantipyrine be present  
in a concentration of about 0.3 mM. An acceptable range is  
from about 0.2 mM to about 0.35 mM. If too much or too  
little 4-aminoantipyrine is present, the reaction will not  
achieve completion, if at all, in the desired time span.

20 It is preferred to include in the system a bacterio-  
cide. The preferred bacteriocide is dichlorophenol, and  
may be provided in a concentration of up to 0.75 mM, pre-  
ferably from about 0.4 to about 0.5 mM.

25 The buffer is provided as required, and can be inor-  
ganic or organic in nature. Phosphates are preferred.  
The presently preferred buffer is potassium dihydrogen  
phosphate ( $\text{KH}_2\text{PO}_4$ ).

30 The preferred acidic compound is cholic acid or a  
metal salt thereof. The presently preferred compound is  
sodium cholate.

The chromogen cholesterol assay compositions of the  
instant invention display the ability to recover, i.e.,  
detect, cholesterol; and preferably provide an assay com-  
pletion time within 10 minutes at 37°C to a pink color,  
35 the developed intensity of which is stable for at least 30

K. R. C.  
4/1/8  
/ 644K. R. C.  
4/1/8  
/ 644

1 additional minutes. The compositions have a projected  
stability of at least 18 months at 4°C, or a shelf life  
of about 6 months at room temperature, as determined by  
a requirement that they are stable for at least 3 days  
5 at 41°C. The chromogen assay systems of the invention  
are used as such and do not require dilution.

- In the chromogen cholesterol assay compositions of  
the instant invention, a lower level of phenol concentra-  
tion defines the point at which the system will lose  
10 stability, and the upper concentration defines the point at  
which phenol has reached a concentration where there may be  
an adverse effect upon color.

Besides being functional as a bacteriocide, dichloro-  
phenol may help speed color development, and therefore is  
15 a highly desirable constituent, independent of its bac-  
teriocide function.

The upper level of buffer concentration is critical.  
If the concentration is too high, completion time will be  
too slow, giving unreliable results and, quite unexpectedly,  
20 there will be an adverse effect on shelf life.

A bile acid or a bile salt is essential. In the  
absence thereof, the system fails to recover cholesterol.  
By contrast, at a concentration above about 5 mM, completion  
25 times are too long for commercial utility.

The nonionic surfactant has been observed to activate  
the enzymes, particularly cholesterol esterase. In its  
absence, reaction time is too long, and if present in too  
high a concentration will result in foaming and may have an  
30 adverse effect on viscosity.



14511

-8-

1 The cholesterol oxidase used in the practice of this  
invention is currently of a microbial nature. The present-  
ly utilized cholesterol oxidase is that manufactured and  
sold by Whatman Biochemicals, Inc., of England. It has  
5 been observed that cholesterol oxidase of the Brevi bac-  
terium is non-functional. Cholesterol esterase is from  
any microbial source, and that used is manufactured and  
sold by Kyowa Hakko Kogyo Company, Ltd., of Japan, under-  
stood to be produced from the microorganism pseudomonas  
10 fluorescens, ATCC 1126. The peroxidase used is, conveni-  
ently, horseradish peroxidase.

The products are prepared by first forming an aqueous  
solution to which there is provided buffer, bile acid or  
salts thereof, and surfactant. Phenol, dichlorophenol and  
15 4-aminoantipyrine are added as required. This base com-  
position is adjusted, if required, to an acceptable pH  
range by addition of a suitable acid or base.

There is separately formed an aqueous solution con-  
taining the nonionic surfactant and the enzymes which are  
20 added. The base solution and the solution of the enzymes  
are then combined to form a net solution.

The following is the presently preferred chromogen  
composition, based on the total volume of 1 liter:

	<u>Component</u>	<u>Concentration</u>
25	Phenol	17 mM
	$\text{KH}_2\text{PO}_4$	12.5 mM
	2,4 dichlorophenol	0.49 mM
	4-aminoantipyrine	0.295 mM
	Cholic acid	2.3 mM
30	Cholesterol oxidase	0.05 KIU/l
	Cholesterol esterase	0.1 KIU/l
	Peroxidase	30 KIU/l
	Triton X-100	0.4 $\pm$ .2 v/v

35

Without limiting, the following Examples and Controls illustrate the various parameters associated with the compositions of the instant invention.

Example 1

There was formulated a cholesterol assay system by forming a clear base solution of the following composition:

	<u>Component</u>	<u>Concentration</u>
10	Water (triple-distilled deionized)	0.955 liter
	Triton X-100 (10% v/v solution)	32.0 ml
	KH <sub>2</sub> PO <sub>4</sub>	12.5 mM
	2,4 dichlorophenol	0.49 mM
	4-aminoantipyrine	0.3 mM
15	Phenol	17.0 mM
	Sodium Cholate	2.3 mM
	pH	7.0

A clear enzyme solution was formed by addition to 10 ml of an aqueous solution containing Triton X-100, sufficient cholesterol oxidase to provide cholesterol oxidase in a net solution of 0.1 KIU/l, cholesterol esterase in an amount sufficient to provide in the net solution a cholesterol esterase concentration of 0.2 KIU/l, and peroxidase in an amount sufficient to provide in the net solution peroxidase in a concentration of 30 KIU/l.

The enzyme solution was combined with the base solution. The solution recovered cholesterol in an assay with less than a 10-minute completion time at 37°C. The color formed had a stability of greater than 30 minutes, and had a lifetime of in excess of 3 days at 41°C, which is an equivalent of a shelf life of 18 months at 4°C and about 6 months at room temperature.

Detailed studies were made of variations of the assay composition prepared according to Example 1. The parameters varied were buffer concentration, pH, cholic acid

1 concentration and nonionic detergent concentration. For  
purposes of all Examples and Controls, the following  
meanings or codes universally apply:

- 5           1       = No change  
           $A_i$      = Initial absorbance at ~~590~~<sup>500</sup> nm at 37°C  
                    must be less than or equal to 0.15 for  
                    a pass  
          2       = A control manufactured and sold by Beckman  
10               Instruments, Inc. that is specific to  
                    cholesterol  
          3       = Mean or principle assigned value (PAV) to  
                    the control times 1 or the factor shown  
          4       = Lot number of Control  
15           5       = A control manufactured and sold by Beckman  
                    Instruments, Inc. for multiple assay,  
                    including cholesterol  
          6       = A cholesterol control manufactured and  
20               sold by New England Reagent Laboratories.  
                    Cholesterol concentration was 200 mg/dl  
          T       = TRITON X-100 = a polyethylene glycol  
                    p- isooctylphenyl ether having an average  
                    formula of  $C_{34}H_{62}O_{11}$  and a formula weight  
                    of 646, manufactured and sold by Eastman  
25               Chemicals

Completion times are for Beckman references at a  
cholesterol concentration of 600 mg/dl.

Color stability is for a cholesterol concentration of  
50 mg/dl (low) and/or 500 mg/dl (high).  
30           Numerical value given is % change at the  
                    time stated.

K. R. C.  
4/1/8.  
1674,

14511

-11-

0091026

1

One or more of the following constitutes failure:

5

- a) no recovery (detection) of cholesterol;
- b) greater than 10 minutes completion time at 37°C; this is failure on the basis that longer completion times are commercially unacceptable;
- c) color stability for less than 30 minutes beyond completion time; and/or
- d) stability for less than three days at 41°C (stressed).

10

Failure is also considered to occur if initial absorbent  $A_i$  is greater than  $\frac{0.15}{1.5}$  and cholesterol recovery (level detected) is not within  $\pm 5\%$  of sample.

15

20

25

30

35

K.R.C.  
4/1/82  
18cm 4/1/82

1

Examples 2-7 and Controls A-CBuffer Concentration

5

The solution, formulated in accordance with Example 1, was modified in respect of  $\text{KH}_2\text{PO}_4$  concentration. All other constituents were kept constant.

10

Table I compares performance as formulated (fresh) and after stressed by being heated to  $41^\circ\text{C}$  for the time specified in the Table. Controls A, B and C failed because of long completion times after stress.

15

20

25

30

35

## 2.5X

Example or Control	Reagent	pH	Color Stability	Buffer Concentration mM/L	Completion Time Minutes	A <sub>1</sub>	Deckman <sup>2</sup> Reference <sup>3</sup> 587.5 C-011044 <sup>4</sup>	Decision I <sup>5</sup> 125, C-007014 <sup>4</sup>	Decision II <sup>5</sup> 139, C-104032 <sup>4</sup>	Decision III <sup>5</sup> 211, C-007016 <sup>4</sup>	2X Decision III <sup>5</sup> 422, 422 <sup>3</sup>	3X Decision III <sup>5</sup> 633, 633 <sup>3</sup>
Example 2	Fresh		0 <sup>1</sup>	0.0	3	.008						
	82 hrs. at 41°C		2.2%		6	.028	615	144	144	229	427	630
Example 3	Fresh		0	1.0	3	.008	604	133	146	225	452	647
	82 hrs. at 41°C		4.0%		7	.028	603	137	144	225	440	646
Example 4	Fresh		0	5.0	3	.008	593	131	142	224	442	653
	82 hrs. at 41°C		2.2%		7	.031	599	133	145	220	442	654
Example 5	Fresh		0	12.5	3	.008	590	130	144	222	443	652
	82 hrs. at 41°C	7.0	1.5%		7	.035	598	132	144	222	441	653
Example 6	Fresh		0	25.0	3	.008	589	131	143	222	441	643
	82 hrs. at 41°C	7.0	0		8.5	.038	604	132	144	222	439	652
Example 7	Fresh		0	50.0	3	.008	588	131	146	222	442	652
	82 hrs. at 41°C		0		8.5	.040	609	130	144	220	439	659
Control A	Fresh		--	75.0	3	.008						
	82 hrs. at 41°C		--		15	.045						
Control B	Fresh		--	100.0	5	.008						
	48 hrs. at 41°C		--		13	.038						
Control C	Fresh		--	200.0	4-5	.008						
	48 hrs. at 41°C		--		25	.053						

1

Examples 8, 9 and Controls D-IEvaluation of pH

5

Using the assay solution prepared according to Example 1, pH was changed using HCl or NaOH to determine its effect on performance. Using the same references of Examples 2-7, the results are shown in Table II.

10

Failures were due to too long a completion time. Controls D, H and I failed as prepared. Controls E and F failed after stressed for 48 hours, while Control G failed after stressed after 82 hours. Color stability was after 45 minutes.

15

20

25

30

35

TABLE II

Example or Control	Reagent	pH	Color Stability	Completion Time Minutes	$\lambda_1$	Beckman Reference 2.5X C-011044	Decision I <sup>1</sup> 125, C-007014	Decision II <sup>2</sup> 139, C-104032	Decision III <sup>3</sup> 211, C-007016	2X Decision III <sup>3</sup> 422	3X Decision III <sup>3</sup> 633
	Condition		Low High								
Control D	Fresh	3.5		14	.008						
Control E	Fresh	4.0		10	.008						
	48 hrs. at 41°C			>30	.188						
Control F	Fresh	5.0		9-3/4	.008						
	48 hrs. at 41°C			FAIL	.072						
Example 8	Fresh	6.0		3-1/2	.008	592	131	148	225	450	667
	48 hrs. at 41°C			5	.026						
	82 hrs. at 41°C		0	7-1/2	.036	593	134	149	229	453	674
Example 9	Fresh	7.0		3	.008	589	130	143	222	441	655
	48 hrs. at 41°C			5	.024						
	82 hrs. at 41°C		3.58	6-1/2-7	.032	594	127	145	226		661
Control G	Fresh	8.0		5-3/4	.008						
	48 hrs. at 41°C			7	.046						
	82 hrs. at 41°C			11	.065						
Control H	Fresh	9.0		>16	.008						
Control I	Fresh	9.5		>15	.008						



1

Examples 10-14 and Controls J, KCholic Acid Effect

5

Using the assay composition of Example 1, cholic acid concentration was varied, with all other factors kept constant. The results are shown in Table III. Control J failed because the system was turbid, and collapsed when applied to human sera. Control K failed because completion time in human sera was too long, even on stress of the solution by heating to 41°C for 72 hours. Color stability was after 75 minutes at 37°C.

15

20

25

30

35

TABLE III

Example or Control	g/l	Cholic Acid	pH	Color Stability	Completion Time		A <sub>1</sub>	NERU <sup>6</sup> 200 mμ/dl	Decision I <sup>5</sup> 124, C-007014 <sup>4</sup>	Decision II <sup>5</sup> 134, C-104032 <sup>4</sup>	Decision 111, 211, C-007016 <sup>4</sup>	2X Decision 111, 422 <sup>5</sup>	3X Decision 111, 633 <sup>5</sup>
					Sera Minutes	Minutes							
Control J	0.0	Fresh 72 hrs. at 41°C		0	(turbidity) COLLAPSE	~5-6	.045	200	114	127	192	278	559
Example 10	0.1	Fresh 72 hrs. at 41°C			7	7	.037						
Example 11	0.3	Fresh 72 hrs. at 41°C			6-1/2	6	.033						
Example 12	0.75	Fresh 72 hrs. at 41°C			6	6	.032						
Example 13	1.0	Fresh 72 hrs. at 41°C		0	5	~5-6	.034		122	135			
Example 14	1.5	Fresh 72 hrs. at 41°C			5-3/4	7	.035						
Control K	2.0	Fresh 72 hrs. at 41°C			10-1/2	~6-7	.036		123	138	209	411	613

0091026

1

Examples 15-20 and Controls L, M

5

Nonionic Surfactant

10

Since the enzymes require some nonionic surfactant in (Triton X-100) for initial enzyme stability, "0" in Control L of Table IV means a concentration on a volume basis of 6 parts per 10,000 parts. Completion times for non-sera were at a cholesterol concentration of 567.5 mg/dl. Cholesterol concentration of the sera used for sera completion time was 650 mg/dl. Control L failed because of too long a completion time in sera.

15

20

25

30

35

TABLE IV

Example or Control	T*	Cond.	pH	Color Stability	Completion Time		$\lambda_1$	NERL 200 mμ/dl	SERA	Decision I <sup>1</sup> 123, C-007014*	Decision -III <sup>1</sup> 211, C-007016*	ZX Decision III <sup>1</sup> 422	JX Decision III <sup>1</sup> 633
					Minutes	Sera Minutes							
				Low / High									
Control L	0.0	Fresh	7.02	21	7	20	.031		263	124	209	408	603
	72 hrs. at 41°C		7.01										
Control M	0.11	Fresh	7.02	21	7.5								
	72 hrs. at 41°C		7.01										
Example 15	0.21	Fresh	7.02	21	7								
	72 hrs. at 41°C		7.01										
Example 16	0.29	Fresh	7.02	21	8								
	72 hrs. at 41°C		7.01										
Example 17	0.38	Fresh		01	7.5	3.5			250	122	206	407	616
	72 hrs. at 41°C												
Example 18	0.70	Fresh	7.02	01	8								
	72 hrs. at 41°C		7.01										
Example 19	1.02	Fresh	7.02		8	3.5							
	72 hrs. at 41°C		7.01										
Example 20	1.34	Fresh	7.02	01	8								
	72 hrs. at 41°C		7.01										

\*Triton X-100 Concentration Percent Volume by Volume

14511

1           Where, in the above Controls, failure is due to too  
long a completion time, as opposed to inability to recover  
cholesterol after stress, it is considered only to define  
a composition considered to have a commercial lack of  
5   utility, as completion time is important. Therefore, the  
specification of the claims is oriented to a commercial  
product of short completion times. It will be considered,  
however, to be in the invention a system having longer  
completion times, provided they have adequate shelf life.

10

15

20

25

30

35

1

WHAT IS CLAIMED IS:

5 1. A stable cholesterol assay composition which comprises an aqueous solution of:

a) at least one acidic compound selected from the group consisting of a bile acid and a salt of a bile acid, the total of said acidic compound being present in an amount of up to about 5mM;

10 b) a nonionic surfactant present in a concentration of from about 0.15 to about 1.5 percent volume by volume;

c) a buffer in a concentration of from 0 to about 65 mM; and

15 d) cholesterol oxidase in a concentration of at least about 0.02 KIU/l, said cholesterol assay solution having a pH of from about 5.5 to about 8.5.

20 2. A stable cholesterol assay composition as claimed in claim 1 which includes microbial cholesterol esterase present in a concentration of at least about 0.07 KIU/l.

25 3. A stable cholesterol assay composition as claimed in claim 1 or 2 which includes a chromogen system for determination of hydrogen peroxide.

30 4. A stable cholesterol assay system as claimed in claim 3 in which the chromogen system comprises phenol in a concentration of from about 8 to about 35 mM, and peroxidase and 4-aminoantipyrine in a concentration sufficient to provide a colormetric quantitative determination of the hydrogen peroxide formed from oxidation of cholesterol.

35

1

5. A stable cholesterol assay system as claimed in claim 1 or 2 which includes a chromogen system for determining hydrogen peroxide and which comprises phenol in a concentration of from about 8 to about 35 mM, 4-aminoantipyrine in a concentration of from about 0.25 to about 0.35 mM, and peroxidase in a concentration of at least about 30 KIU/l.

10

6. A stable cholesterol assay composition as claimed in any one of the previous claims which includes a bacteriocide.

15

7. A stable cholesterol assay composition as claimed in claim 6 which includes 2,4 dichlorophenol in a concentration of up to about 1 mM.

20

8. A stable cholesterol assay composition as claimed in any one of the previous claims in which the nonionic surfactant is polyethylene glycol p-isooctylphenyl ether.

25

9. A stable cholesterol assay composition as claimed in any one of the previous claims in which the buffer is potassium dihydrogen phosphate.

30

10. A stable cholesterol assay composition as claimed in any one of the previous claims in which the acidic compound is a metal salt of cholic acid.

35

1

11. A stable total cholesterol chromogen assay composition comprising an aqueous solution having a pH of from about 6.5 to about 8.5 and comprising:

5

a) phenol in a concentration of from about 8 to about 35 mM;

b) a metal salt of cholic acid present in a concentration of up to about 5 mM;

c) a nonionic surfactant present in a  
10 concentration of from about 0.2 to about 1.5 percent volume by volume;

d) a buffer present in a concentration of from 0 to about 65 mM;

e) 4-aminoantipyrine;

15

f) microbial cholesterol esterase present in a concentration of at least about 0.07 KIU/l;

g) cholesterol oxidase present in a concentration of at least about 0.02 KIU/l; and

20

h) peroxidase,  
the amount of peroxidase and 4-aminoantipyrine being sufficient to enable quantitative determination of the amount of hydrogen peroxide formed from oxidation of cholesterol.

25

12. A stable total cholesterol chromogen assay composition as claimed in claim 11 in which the buffer is potassium dihydrogen phosphate and pH is from about 6 to about 7.5.

30

13. A stable total cholesterol chromogen assay composition as claimed in claim 11 or 12 in which the nonionic surfactant is present in a concentration of from about 0.2 to about 0.4 percent volume by volume and is polyethylene glycol p-isooctylphenyl ether.

35



1

14. A stable total cholesterol chromogen assay composition as claimed in any one of the previous claims in which peroxidase is present in a concentration of at least about 30 KIU/l and in which 4-aminoantipyrine is present in a concentration of about 0.3 mM.

5

10

15. A stable total cholesterol chromogen assay composition comprising an aqueous solution of:

10

a) phenol in a concentration of about 17 mM;

b) 2,4 dichlorophenol present in a concentration of about 0.5 mM;

c) a metal salt of cholic acid present in a concentration of up to about 5 mM;

15

d) polyethylene glycol p-isooctylphenyl ether present in a concentration of from about 0.2 to about 0.6 percent volume by volume;

e)  $\text{KH}_2\text{PO}_4$  present in a concentration of about 12.5 mM;

20

f) peroxidase present in a concentration of about 30 KIU/l;

g) cholesterol oxidase present in a concentration of at least about 0.05 KIU/l;

h) microbial cholesterol esterase present in a concentration of at least about 0.1 KIU/l; and

25

i) 4-aminoantipyrine present in a concentration of about 0.3 mM,

said stable total cholesterol chromogen assay composition having a pH of from about 6.0 to about 7.5.

30

35

14511

-5-

16. A method for preparing a stable cholesterol assay solution which comprises forming a base solution and an enzyme solution, then combining the base solution and the enzyme solution to form a net solution, and in which:

a) the base solution is formed by dissolving in water:

i) at least one acidic compound selected from the group consisting of a bile acid and a salt of a bile acid to provide the total of said acidic compound in the net solution in an amount of up to about 5 mM;

ii) a nonionic surfactant determined to provide an amount in the net solution a nonionic surfactant concentration of from about 0.15 to about 1.5 percent volume by volume;

b) the enzyme solution being formed by dissolving in water containing a portion of the total nonionic surfactant, cholesterol oxidase to provide in the net solution cholesterol oxidase in a concentration of at least about 0.02 KIU/l, the base solution being adjusted if required to provide a net solution having a pH of from about 5.5 to about 8.5.

17. A method as claimed in claim 16 in which there is added to the enzyme solution microbial cholesterol esterase in an amount to provide in the net solution cholesterol esterase in a concentration of at least about 0.07 KIU/l.

1

18. A method as claimed in claim 16 or 17 in which there is added to the base solution phenol in an amount sufficient to provide in the net solution phenol in a concentration of from about 8 to about 15 mM, and 4-aminoantipyrine, and in which there is added to the enzyme solution peroxidase, the amount of peroxidase and 4-aminoantipyrine being sufficient in the net solution to enable quantitative colormetric determination of the amount of hydrogen peroxide formed from oxidation of cholesterol.

15

20

25

30

35



(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets

(11)

Publication number:

**0 091 026****A3**

(12)

**EUROPEAN PATENT APPLICATION**

(21)

Application number: 83102958.2

(51)

Int. Cl.<sup>4</sup>: **C 12 Q 1/60****C 12 Q 1/46**

(22)

Date of filing: 24.03.83

(30)

Priority: 02.04.82 US 364899

(43)

Date of publication of application:  
12.10.83 Bulletin 83/41

(88)

Date of deferred publication of search report: 10.07.85

(84)

Designated Contracting States:  
AT BE CH DE FR GB IT LI LU NL SE

(71)

Applicant: **Modrovich, Ivan Endre**  
829 Via Alondra  
Camarillo California 93010(US)

(72)

Inventor: **Modrovich, Ivan Endre**  
829 Via Alondra  
Camarillo California 93010(US)

(72)

Inventor: **Caris, Karen Rae**  
1399 North Lucero Street  
Camarillo California 93010(US)

(74)

Representative: **Patentanwälte Grünecker, Dr.**  
**Kinkeldey, Dr. Stockmair, Dr. Schumann, Jakob, Dr.**  
**Bezold, Meister, Hilgers, Dr. Meyer-Plath**  
Maximilianstrasse 58  
D-8000 München 22(DE)

(54)

**Improved time-stable liquid cholesterol assay compositions.**

(57)

There is provided a stable cholesterol assay composition which comprises an aqueous solution of at least one bile acid or salt thereof being present in an amount of up to about 5mM; a nonionic surfactant present in an amount of from about 0.15 to about 1.5 percent volume by volume; a buffer in a concentration of from 0 to about 65 mM; and cholesterol oxidase in a concentration of at least about 0.2 KIU/l. Solution pH is from about 5.5 to about 8.5. Addition of cholesterol esterase, phenol, peroxidase and 4-amino-antipyrine provides a total cholesterol chromogen system.

**EP 0 091 026 A3**



European Patent  
Office

# EUROPEAN SEARCH REPORT

0091026  
Application number

EP 83 10 2958

## DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. <sup>3</sup> )
D,Y	EP-A-0 024 578 (MODROVICH) * Pages 28-33, examples I, II *	1,2,16	C 12 Q 1/60 C 12 Q 1/46 // C 12 Q 1/28
A	---	3-6,9, 10,12	
Y	CLINICAL CHEMISTRY, vol. 25, no. 6, june 1979, Easton, Pennsylvania, USA; P.J.G. DAWSON et al. "Enzymic Assay of Total Cholesterol Involving Chemical or Enzymic Hydrolysis - A Comparison of Methods", pages 976-984 * Page 976, righthand column, paragraph 2; page 978, figures 2,3, table I *	1,2,16	
A	---	1	TECHNICAL FIELDS SEARCHED (Int. Cl. <sup>2</sup> )
A	US-A-4 226 713 (GOLDBERG) * Column 6, line 28 - column 8, line 8 *	1	C 12 Q 1/00 G 01 N 33/00
A	---	1	
A	GB-A-1 479 994 (ABBOTT LABORATORIES) * Page 3, lines 7-27 *		
	-----		
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 21-01-1985	Examiner GREEN C.H.

### CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone  
Y : particularly relevant if combined with another document of the same category  
A : technological background  
O : non-written disclosure  
P : intermediate document

T : theory or principle underlying the invention  
E : earlier patent document, but published on, or after the filing date  
D : document cited in the application  
L : document cited for other reasons  
& : member of the same patent family, corresponding document